Glynn Gilcrease III
( out of 123 reviews )

Glynn Gilcrease III, MD

Languages spoken: English, Spanish

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Clinic 3A, Gastrointestinal
Salt Lake City
801-587-4700

  • Dr. G. Weldon Gilcrease, MD is an Associate Professor in the Oncology Division at the University of Utah School of Medicine and a Huntsman Cancer Institute (HCI) investigator. He specializes in gastrointestinal cancers and patients enrolled in early phase trials. Dr. Gilcrease is also the Program Director for the Hematology/Oncology Fellowship program at the University of Utah School of Medicine and a Huntsman Cancer Institute (HCI).

    Dr. Gilcrease focuses on early phase clinical trials and drug development. He is involved in preclinical research and Phase I/II trials for patients affected with inoperable colorectal cancer. His research entails exploiting important pathways that drive cancer, including the beta-catenin pathway in colorectal cancer. He hopes to bring novel and targeted therapies into the clinic to benefit patients.

    Dr. Gilcrease has been at the University of Utah since 2009. He completed a hematology/oncology fellowship at the University of Utah and HCI where he was awarded the Outstanding Fellow Teaching Award in 2011. Prior to that he completed his residency at Scripps Mercy Hospital in San Diego, CA where he received the Outstanding Resident Award for his medical care and dedication to learning and teaching. He served as Chief Resident after completing his residency. He earned his medical degree from the University of Arizona.

    Specialties

    Board Certification

    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Medical Examiners

    Patient Rating

    4.9 /5
    ( out of 123 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    August 24, 2023
    HUNTSMAN CANCER CENTER

    So lucky to have him as my doctor. I felt hopeful about my upcoming treatment and the treatment plan

    August 21, 2023
    HUNTSMAN CANCER CENTER

    Have been seeing him for many years and always trust his diagnosis and treatment plan.

    August 19, 2023
    HUNTSMAN CANCER CENTER

    He is the best. He cares about my treatment and condition, takes the time to discuss and explain treatment options, and go the extra mile to insure I have all the available options. I couldn't ask for a finer doctor.

    August 08, 2023
    HUNTSMAN CANCER CENTER

    Truly one of the best doctors you'll ever find.

    July 28, 2023
    HUNTSMAN CANCER CENTER

    We truly appreciated the doctor's manner and ability to explain the next steps.

    July 19, 2023
    HUNTSMAN CANCER CENTER

    Fue muy amable, mucha atencion y explicacion de mi caso

    July 16, 2023
    HUNTSMAN CANCER CENTER

    He provided an expanded set of options that was highly valuable

    May 26, 2023
    HUNTSMAN CANCER CENTER

    Very welcoming,warm and caring person Seems to have a great team working with him

    May 22, 2023
    FARMINGTON HEALTH CENTER

    He is the BEST!

    See More Patient Comments

  • Dr. G. Weldon Gilcrease, MD is an Associate Professor in the Oncology Division at the University of Utah School of Medicine and a Huntsman Cancer Institute (HCI) investigator. He specializes in gastrointestinal cancers and patients enrolled in early phase trials. Dr. Gilcrease is also the Program Director for the Hematology/Oncology Fellowship program at the University of Utah School of Medicine and a Huntsman Cancer Institute (HCI).

    Dr. Gilcrease focuses on early phase clinical trials and drug development. He is involved in preclinical research and Phase I/II trials for patients affected with inoperable colorectal cancer. His research entails exploiting important pathways that drive cancer, including the beta-catenin pathway in colorectal cancer. He hopes to bring novel and targeted therapies into the clinic to benefit patients.

    Dr. Gilcrease has been at the University of Utah since 2009. He completed a hematology/oncology fellowship at the University of Utah and HCI where he was awarded the Outstanding Fellow Teaching Award in 2011. Prior to that he completed his residency at Scripps Mercy Hospital in San Diego, CA where he received the Outstanding Resident Award for his medical care and dedication to learning and teaching. He served as Chief Resident after completing his residency. He earned his medical degree from the University of Arizona.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Medical Examiners

    Education history

    Fellowship Arizona Center for Integrative Medicine Fellow
    Hematology and Oncology - University of Utah Fellow
    Chief Resident Scripps Mercy Hospital Chief Medical Resident
    Scripps Mercy Hospital Intern/Resident
    Professional Medical Medicine - The University of Arizona College of Medicine M.D.
    Spanish, Summa Cum Laude - The University of Arizona, Tucson B.A.
    Undergraduate Mathematics & Computer Science, Summa Cum Laude with Honors: Honors Thesis in Mathematics Titled Young Tableaux and Semi-Invariance of Symmetric Groups - The University of Arizona, Tucson B.S.

    Selected Publications

    Journal Article

    1. Gumbleton M, Allan S, Conway H, Boucher K, Marvin J, Hawks J, Burnett W, Van Brocklin M, Whisenant J, Gilcrease G, Gupta S (2023). A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC Res Notes, 16(1), 16. (Read full article)
    2. Pauley K, Koptiuch C, Greenberg S, Kohlmann W, Jeter J, Colonna S, Werner T, Kinsey C, Gilcrease G, Weis J, Whisenant J, Florou V, Garrido-Laguna I (2022). Discrepancies between tumor genomic profiling and germline genetic testing. ESMO Open, 7(4), 100526. (Read full article)
    3. Martin DB, Stetson PD, Gilcrease GW, Stillman RC, Sugalski JM, Skinner J, Levy M (2021). Preferences in Oncology History Documentation Styles Among Clinical Practitioners. JCO Oncol Pract, 18(1), e1-e8. (Read full article)
    4. Martin DB, Stetson PD, Gilcrease GW, Stillman RC, Sugalski JM, Skinner J, Levy M (2021). Preferences in Oncology History Documentation Styles Among Clinical Practitioners. JCO Oncol Pract, 18(1), OP2000756. (Read full article)
    5. Florou V, Nevala-Plagemann C, Whisenant J, Maeda P, Gilcrease GW, Garrido-Laguna I (2021). Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib. J Natl Compr Canc Netw, 19(5), 478-482. (Read full article)
    6. Wells SM, Boothe D, Ager BJ, Tao R, Gilcrease GW 3rd, Lloyd S (2020). Analysis of Nonsurgical Treatment Options for Metastatic Rectal Cancer. Clin Colorectal Cancer, 19(2), 91-99.e1. (Read full article)
    7. Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna I (2019). Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. ESMO Open, 4(4), e000539. (Read full article)
    8. Weldon Gilcrease G, Stenehjem DD, Wade ML, Weis J, McGregor K, Whisenant J, Boucher KM, Thorne K, Orgain N, Garrido-Laguna I, Sharma S (2018). Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer. Invest New Drugs, 37(3), 482-489. (Read full article)
    9. Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon M (2019). Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med, 25(4), 620-627. (Read full article)
    10. Lloyd S, Baraghoshi D, Tao R, Garrido-Laguna I, Gilcrease GW 3rd, Whisenant J, Weis JR, Scaife C, Pickron TB, Huang LC, Monroe MM, Abdelaziz S, Fraser AM, Smith KR, Deshmukh V, Newman M, Rowe KG, Snyder J, Samadder NJ, Hashibe M (2019). Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival. Am J Clin Oncol, 42(4), 355-362. (Read full article)
    11. Samadder NJ, Smith KR, Hanson H, Pimentel R, Wong J, Boucher K, Akerley W, Gilcrease G, Ulrich CM, Burt RW, Curtin K (2016 Mar). Familial Risk in Patients With Carcinoma of Unknown Primary. JAMA Oncol, 2(3), 340-346.
    12. Soldi R, Horrigan SK, Cholody MW, Padia J, Sorna V, Bearss J, Gilcrease G, Bhalla K, Verma A, Vankayalapati H, Sharma S (2015). Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-Catenin Pathway Inhibitors. J Med Chem, 58(15), 5854-62. (Read full article)
    13. Ettinger DS, Handorf CR, Agulnik M, Bowles DW, Cates JM, Cristea M, Dotan E, Eaton KD, Fidias PM, Gierada D, Gilcrease GW, Godby K, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Schwab RB, Shulman LN, Smerage JB, Stevenson MM, Varadhachary GR, Zager JS, Zhen WK, Bergman MA, Freedman-Cass DA, National Comprehensive Cancer Network (2014). Occult primary, version 3.2014. J Natl Compr Canc Netw, 12(7), 969-74. (Read full article)
    14. Garrido-Laguna I, McGregor KA, Wade M, Weis J, Gilcrease W, Burr L, Soldi R, Jakubowski L, Davidson C, Morrell G, Olpin JD, Boucher K, Jones D, Sharma S (2013). A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Invest New Drugs, 31(5), 1257-64. (Read full article)
    15. Kimura BJ, Gilcrease GW 3rd, Showalter BK, Phan JN, Wolfson T (2012). Diagnostic performance of a pocket-sized ultrasound device for quick-look cardiac imaging. Am J Emerg Med, 30(1), 32-6. (Read full article)
    16. Kimura BJ, Dalugdugan R, Gilcrease GW 3rd, Phan JN, Showalter BK, Wolfson T (2011). The effect of breathing manner on inferior vena caval diameter. Eur J Echocardiogr, 12(2), 120-3. (Read full article)
    17. Gilcrease GW, Stein JB (2010). A delayed case of fatal atrioesophageal fistula following radiofrequency ablation for atrial fibrillation. J Cardiovasc Electrophysiol, 21(6), 708-11. (Read full article)

    Case Report

    1. Nelson KL, Stenehjem D, Driscoll M, Gilcrease GW (2017). Fatal Statin-Induced Rhabdomyolysis by Possible Interaction with Palbociclib. Front Oncol, 7, 150. (Read full article)

    Other

    1. Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon M (2019). Publisher Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med (25(5), p. 861). United States. (Read full article)

  • News & Podcasts